Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161590 · ClinicalTrials.gov registry record · Phase 1
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
A Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00161590: Completed Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins, sponsored by Weill Medical College of Cornell University.
NCT00161590 is a Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins that has completed, run by Weill Medical College of Cornell University. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00161590, a Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
Primary Objective: * To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell lymphomas. Secondary Objectives: * To evaluate response rate, overall survival, and disease-free survival in patients with T-cell, null-cell, and NK-cell lymphomas treated with Campath + CHOP chemotherapy. * To assess the incidence of cytomegalovirus (CMV) reactivation in patients with these lymphomas treated with the Campath + CHOP combination. * To determine features which might be predictive of resistance to treatment or predictive of relapse, including the absence of glycosylphosphatidylinositol (GPI)-linked proteins.
Conditions Studied
Interventions
- DRUG CHOP and alemtuzumab
Study Locations (1)
New York
- Weill Medical College of Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | Phase 1 |
What the finished NCT00161590 record still lists
NCT00161590 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CHOP and alemtuzumab is the first listed.
NCT00161590 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00161590 about?
NCT00161590 is a clinical study titled "Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma". Primary Objective: * To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell lymphomas. Secondary Objecti...
What is the current status of trial NCT00161590?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-07.
What conditions does trial NCT00161590 study?
This clinical trial studies the following conditions: T-Cell Lymphoma, Lymphoma, Non-Hodgkins.
What interventions are being tested in trial NCT00161590?
The interventions under investigation include: CHOP and alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT00161590?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00161590 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of Tazemetostat in Lymphoid Malignancies
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CD4CAR for CD4+ Leukemia and Lymphoma
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia